New #JITC article: Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab ow.ly/NItm50GyIpC Allison Betof Warner, MD, PhD Jedd Wolchok Michael Postow

Women scientists have been disproportionately impacted by the pandemic. nature.com/articles/s4146…

Stunning NEW research presented FIRST TIME in ASCO Plenary Series: ECOG-ACRIN Cancer Research Group phase III DREAMseq by Dr. Atkins Georgetown Lombardi=> Even for oncogene-driven melanoma: IO 1st rather than targeted therapy leads to better survival for most patients! Kimmie Ng, MD, MPH Melissa L. Johnson Robin Zon, MD, FACP, FASCO

JUST IN via ASCO alert: U.S. FDA approved pembrolizumab Merck for the adjuvant treatment of adult & pediatric (≥12 y) patients w/stage IIB/IIC melanoma post resection. Results based on KEYNOTE-716 presented Jason Luke, MD, FACP ESMO - Eur. Oncology #ESMO21 OncoAlert accessdata.fda.gov/drugsatfda_doc…

#ASHKudos Raj Chakraborty for 🤩😎 talk on QOL in long term #myeloma #BMT survivors from Fred Hutchinson Cancer Center #iNSPIRE/CIBMTR #SCP studies

What intussusception actually looks like 🤯 Via Andre Moreira GrepMed #MedTwitter

So proud Dr. Jennifer McQuade Chris(tine) Spencer Jennifer Wargo MD Carrie Daniel Mac Melanoma team MD Anderson Cancer Center for paving way to harness power of microbiome & improve IO outcomes Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response science.org/doi/10.1126/sc…

On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy nejm.org/doi/full/10.10…

I think about this sign almost every day.

Congratulations Immunocore and all patients dealing with #ocularmelanoma !!! #KIMMTRAK #tebetefusp approved by U.S. FDA FDA Oncology !! A major step forward for our patients. Blessed to have been part of this The Angeles Clinic ir.immunocore.com/news-releases/…

New data led by Tammy Sussman MD on impact of #TE on survival in pts with melanoma receiving chemo and/or IO #ASCO2022 #CleClinicCancer. Poster up now.

Check out our article Relatlimab Shows Efficacy Against LAG-3 in Melanoma dailynews.ascopubs.org/do/10.1200/ADN… #ASCODailyNews ASCO With Patrick Ott Dana-Farber

Forget your sunscreen? Mass General Brigham has got you covered 🧴🧴🧴IMPACT Melanoma

JUST IN: For the 22nd consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News Health! And photos from few min ago while coming to work ! Dana-Farber The Jimmy Fund Dana-Farber Lank Center for Genitourinary Oncology ms.spr.ly/6016jE6vE

#ESMO2022 Melanoma Session- Prof. Dirk Schaddendorf presenting OS benefit from adjuvant high dose ipi (3) + nivo (1) in resected/radiated Stage IV melanoma - IMMUNED study now published in ⁦The Lancet⁩. Impressive outcome including some patients with Brain Mets post-SRS

Incredible achievement positive Phase 3 trial with TIL congrats John Haanen & colleagues @NKI. Game changer/new era to improve patient outcomes. FDA approval never too soon! Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma | NEJM nejm.org/doi/full/10.10…

Today my great grandmother, Lily Ebert, an Auschwitz survivor, turns 99! “I never thought I would survive Auschwitz and have another birthday. At 99, I celebrate to show that the Nazis did not win!” All #HappyBirthdayLily wishes and comments will be passed on to Lily. ❤️

Saw this on my commute into work this morning. Love it 😂 and so accurate!